×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
OMER – omeros corporation (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
OMER
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/1
01:23 pm
omer
Omeros (NASDAQ:OMER) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $36.00 price target on the stock.
Low
Report
Omeros (NASDAQ:OMER) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $36.00 price target on the stock.
12/1
08:41 am
omer
Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros' Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906) [Yahoo! Finance]
Medium
Report
Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros' Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906) [Yahoo! Finance]
12/1
08:30 am
omer
Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros’ Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)
Medium
Report
Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros’ Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)
11/21
06:58 pm
omer
Omeros: Key Milestone Ahead, Risk-Averse Investors Should Avoid [Seeking Alpha]
Medium
Report
Omeros: Key Milestone Ahead, Risk-Averse Investors Should Avoid [Seeking Alpha]
11/17
01:19 pm
omer
Omeros Corporation (OMER) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Medium
Report
Omeros Corporation (OMER) Q3 2025 Earnings Call Transcript [Seeking Alpha]
11/14
04:18 pm
omer
Omeros (NASDAQ:OMER) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $36.00 price target on the stock.
High
Report
Omeros (NASDAQ:OMER) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $36.00 price target on the stock.
11/11
09:31 am
omer
Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2025 [Yahoo! Finance]
Medium
Report
Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2025 [Yahoo! Finance]
11/11
08:30 am
omer
Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2025
Medium
Report
Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2025
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/1
08:30 am
omer
Form 8-K OMEROS CORP For: Nov 25
Medium
Report
Form 8-K OMEROS CORP For: Nov 25
10/31
11:05 am
omer
Form SCHEDULE 13G/A OMEROS CORP Filed by: VANGUARD GROUP INC
Low
Report
Form SCHEDULE 13G/A OMEROS CORP Filed by: VANGUARD GROUP INC
10/15
07:16 pm
omer
Form 4 OMEROS CORP For: Oct 13 Filed by: Demopulos Gregory A MD
Low
Report
Form 4 OMEROS CORP For: Oct 13 Filed by: Demopulos Gregory A MD
10/15
08:30 am
omer
Form 8-K OMEROS CORP For: Oct 10
High
Report
Form 8-K OMEROS CORP For: Oct 10
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/2
Omeros Corporation Reports Updated Results from Narsoplimab HSCT-TMA Clinical Trial and Highlights from Recent Clinical and CMC Meetings with FDA
55.4%
3/31 Omeros Co. (NASDAQ: OMER) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $12.00 price target on the stock. 17.3%
5/10 Omeros Co. (NASDAQ: OMER) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 13.6%
8/8 Q2/2019 6/30/2019 EPS -0.290 ZacksConsensus -0.450 ActVsEst 0.160 - Beat 11.9%
10/28 Omeros Corporation Initiates BLA Submission for Narsoplimab for the Treatment of HSCT-TMA 6.2%
8/5 Omeros Corporation to Announce Second Quarter 2019 Financial Results on August 8, 2019 6.0%
2/4 Omeros Co. (NASDAQ: OMER) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 4.9%
11/4 Omeros Corporation Announces Publication of Study Results on the Impact of OMIDRIA on Opioid Use and Pain 4.6%
11/19 Omeros Presents New GPR174 Immuno-oncology Data Today at the American Association for Cancer Research Conference in Boston 4.6%
8/12 Omeros Co. (NASDAQ: OMER) was given a new $32.00 price target on by analysts at Maxim Group. They now have a "buy" rating on the stock. 4.2%
3/31 Omeros Co. (NASDAQ: OMER) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $12.00 price target on the stock. 17.3%
5/10 Omeros Co. (NASDAQ: OMER) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 13.6%
8/8 Q2/2019 6/30/2019 EPS -0.290 ZacksConsensus -0.450 ActVsEst 0.160 - Beat 11.9%
10/28 Omeros Corporation Initiates BLA Submission for Narsoplimab for the Treatment of HSCT-TMA 6.2%
8/5 Omeros Corporation to Announce Second Quarter 2019 Financial Results on August 8, 2019 6.0%
2/4 Omeros Co. (NASDAQ: OMER) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 4.9%
11/4 Omeros Corporation Announces Publication of Study Results on the Impact of OMIDRIA on Opioid Use and Pain 4.6%
11/19 Omeros Presents New GPR174 Immuno-oncology Data Today at the American Association for Cancer Research Conference in Boston 4.6%
8/12 Omeros Co. (NASDAQ: OMER) was given a new $32.00 price target on by analysts at Maxim Group. They now have a "buy" rating on the stock. 4.2%
TOP News Decliners
12/4
Omeros Co. (NASDAQ: OMER) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
-12.8%
5/6 Omeros Corporation to Announce First Quarter 2019 Financial Results on May 9, 2019 -9.3%
3/10 Omeros Co. (NASDAQ: OMER) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -8.7%
1/17 Omeros Co. (NASDAQ: OMER) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -7.8%
5/23 Omeros (OMER) Presents At UBS Global Healthcare Conference - Slideshow [Seeking Alpha] -5.9%
3/6 Omeros Co. (NASDAQ: OMER) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. -5.7%
3/12 Omeros Co. (NASDAQ: OMER) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -5.7%
10/30 Omeros Co. (NASDAQ: OMER) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.4%
2/25 Omeros Co. (NASDAQ: OMER) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -5.3%
12/27 Omeros Co. (NASDAQ: OMER) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -4.7%
5/6 Omeros Corporation to Announce First Quarter 2019 Financial Results on May 9, 2019 -9.3%
3/10 Omeros Co. (NASDAQ: OMER) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -8.7%
1/17 Omeros Co. (NASDAQ: OMER) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -7.8%
5/23 Omeros (OMER) Presents At UBS Global Healthcare Conference - Slideshow [Seeking Alpha] -5.9%
3/6 Omeros Co. (NASDAQ: OMER) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. -5.7%
3/12 Omeros Co. (NASDAQ: OMER) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -5.7%
10/30 Omeros Co. (NASDAQ: OMER) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.4%
2/25 Omeros Co. (NASDAQ: OMER) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -5.3%
12/27 Omeros Co. (NASDAQ: OMER) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -4.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: